These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8913340)

  • 1. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
    Nitiss JL; Wang JC
    Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
    Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
    Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
    Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
    Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae.
    Fiorani P; Bjornsti MA
    Ann N Y Acad Sci; 2000; 922():65-75. PubMed ID: 11193926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
    Osheroff N; Corbett AH; Elsea SH; Westergaard M
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S19-25. PubMed ID: 8070023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using yeast to understand drugs that target topoisomerases.
    Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J
    Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498
    [No Abstract]   [Full Text] [Related]  

  • 11. Aclacinomycin A stabilizes topoisomerase I covalent complexes.
    Nitiss JL; Pourquier P; Pommier Y
    Cancer Res; 1997 Oct; 57(20):4564-9. PubMed ID: 9377570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
    Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
    Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
    Nitiss JL; Liu YX; Hsiung Y
    Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerases as targets for anticancer drugs.
    Topcu Z
    J Clin Pharm Ther; 2001 Dec; 26(6):405-16. PubMed ID: 11722677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
    Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
    Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
    Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
    Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.